Do analysts prefer BCLI or MIRA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainstorm Cell Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, BCLI or MIRA?

MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Brainstorm Cell Therapeutics N/A N/A -$11.62M -$1.64 N/A MIRA Pharmaceuticals N/A N/A -$10.44M -$1.30 N/A

Is BCLI or MIRA more profitable?

Brainstorm Cell Therapeutics' return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Brainstorm Cell Therapeutics N/A N/A -519.50% MIRA Pharmaceuticals N/A -140.82% -135.01%

Does the media refer more to BCLI or MIRA?

In the previous week, Brainstorm Cell Therapeutics and Brainstorm Cell Therapeutics both had 1 articles in the media. MIRA Pharmaceuticals' average media sentiment score of 0.75 beat Brainstorm Cell Therapeutics' score of 0.00 indicating that MIRA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Brainstorm Cell Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MIRA Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer BCLI or IXHL?

Incannex Healthcare has a consensus target price of $18.00, suggesting a potential upside of 453.85%. Given Incannex Healthcare's higher probable upside, analysts plainly believe Incannex Healthcare is more favorable than Brainstorm Cell Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainstorm Cell Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Incannex Healthcare 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is BCLI or IXHL more profitable?

Brainstorm Cell Therapeutics' return on equity of 0.00% beat Incannex Healthcare's return on equity. Company Net Margins Return on Equity Return on Assets Brainstorm Cell Therapeutics N/A N/A -519.50% Incannex Healthcare N/A -81.01% -76.11%

Do analysts prefer BTAI or BCLI?

BioXcel Therapeutics currently has a consensus price target of $11.00, suggesting a potential upside of 739.69%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe BioXcel Therapeutics is more favorable than Brainstorm Cell Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Brainstorm Cell Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is BTAI or BCLI more profitable?

Brainstorm Cell Therapeutics has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. Company Net Margins Return on Equity Return on Assets BioXcel Therapeutics -11,078.53% N/A -201.53% Brainstorm Cell Therapeutics N/A N/A -519.50%

Do analysts recommend GOSS or BCLI?

Gossamer Bio currently has a consensus target price of $5.00, suggesting a potential upside of 2,858.58%. Given Gossamer Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Gossamer Bio is more favorable than Brainstorm Cell Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gossamer Bio 2 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.20 Brainstorm Cell Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is GOSS or BCLI more profitable?

Brainstorm Cell Therapeutics has a net margin of 0.00% compared to Gossamer Bio's net margin of -324.82%. Company Net Margins Return on Equity Return on Assets Gossamer Bio -324.82% N/A -96.10% Brainstorm Cell Therapeutics N/A N/A -519.50%

Does the media prefer GOSS or BCLI?

In the previous week, Gossamer Bio and Gossamer Bio both had 1 articles in the media. Gossamer Bio's average media sentiment score of 0.00 equaled Brainstorm Cell Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gossamer Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Brainstorm Cell Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate BCLI or INMB?

INmune Bio has a consensus target price of $8.00, suggesting a potential upside of 492.59%. Given INmune Bio's stronger consensus rating and higher probable upside, analysts plainly believe INmune Bio is more favorable than Brainstorm Cell Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainstorm Cell Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 INmune Bio 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.17

Is BCLI or INMB more profitable?

Brainstorm Cell Therapeutics' return on equity of 0.00% beat INmune Bio's return on equity. Company Net Margins Return on Equity Return on Assets Brainstorm Cell Therapeutics N/A N/A -519.50% INmune Bio N/A -103.03% -77.66%

Does the media favor BCLI or INMB?

In the previous week, INmune Bio had 1 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 2 mentions for INmune Bio and 1 mentions for Brainstorm Cell Therapeutics. Brainstorm Cell Therapeutics' average media sentiment score of 0.00 equaled INmune Bio'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Brainstorm Cell Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral INmune Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Brainstorm Cell Therapeutics (BCLI) Competitors

$0.94 +0.03 (+3.04%)

As of 06/24/2026 03:27 PM Eastern

Compare

BCLI vs. MIRA, IXHL, BTAI, GOSS, and INMB

Should you buy Brainstorm Cell Therapeutics stock or one of its competitors? MarketBeat compares Brainstorm Cell Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Brainstorm Cell Therapeutics include MIRA Pharmaceuticals (MIRA), Incannex Healthcare (IXHL), BioXcel Therapeutics (BTAI), Gossamer Bio (GOSS), and INmune Bio (INMB). These companies are all part of the "pharmaceutical products" industry.

How does Brainstorm Cell Therapeutics compare to MIRA Pharmaceuticals?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Brainstorm Cell Therapeutics' return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%

MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.64	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A

14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are held by insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Brainstorm Cell Therapeutics has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainstorm Cell Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Brainstorm Cell Therapeutics and Brainstorm Cell Therapeutics both had 1 articles in the media. MIRA Pharmaceuticals' average media sentiment score of 0.75 beat Brainstorm Cell Therapeutics' score of 0.00 indicating that MIRA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Brainstorm Cell Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MIRA Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MIRA Pharmaceuticals beats Brainstorm Cell Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Brainstorm Cell Therapeutics compare to Incannex Healthcare?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are owned by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are owned by company insiders. Comparatively, 1.3% of Incannex Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Brainstorm Cell Therapeutics' return on equity of 0.00% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%
Incannex Healthcare	N/A	-81.01%	-76.11%

Incannex Healthcare has a consensus target price of $18.00, suggesting a potential upside of 453.85%. Given Incannex Healthcare's higher probable upside, analysts plainly believe Incannex Healthcare is more favorable than Brainstorm Cell Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainstorm Cell Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Brainstorm Cell Therapeutics has higher earnings, but lower revenue than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.64	N/A
Incannex Healthcare	$90K	432.25	-$46.88M	-$1.55	N/A

Brainstorm Cell Therapeutics has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market. Comparatively, Incannex Healthcare has a beta of 7, suggesting that its share price is 600% more volatile than the broader market.

In the previous week, Brainstorm Cell Therapeutics had 1 more articles in the media than Incannex Healthcare. MarketBeat recorded 1 mentions for Brainstorm Cell Therapeutics and 0 mentions for Incannex Healthcare. Brainstorm Cell Therapeutics' average media sentiment score of 0.00 equaled Incannex Healthcare'saverage media sentiment score.

Company	Overall Sentiment
Brainstorm Cell Therapeutics	Neutral
Incannex Healthcare	Neutral

Summary

Brainstorm Cell Therapeutics and Incannex Healthcare tied by winning 6 of the 12 factors compared between the two stocks.

How does Brainstorm Cell Therapeutics compare to BioXcel Therapeutics?

BioXcel Therapeutics (NASDAQ:BTAI) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

BioXcel Therapeutics currently has a consensus price target of $11.00, suggesting a potential upside of 739.69%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe BioXcel Therapeutics is more favorable than Brainstorm Cell Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Brainstorm Cell Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Brainstorm Cell Therapeutics had 1 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 1 mentions for Brainstorm Cell Therapeutics and 0 mentions for BioXcel Therapeutics. BioXcel Therapeutics' average media sentiment score of 0.00 equaled Brainstorm Cell Therapeutics'average media sentiment score.

Company	Overall Sentiment
BioXcel Therapeutics	Neutral
Brainstorm Cell Therapeutics	Neutral

Brainstorm Cell Therapeutics has lower revenue, but higher earnings than BioXcel Therapeutics. Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioXcel Therapeutics	$640K	63.21	-$69.90M	-$5.75	N/A
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.64	N/A

Brainstorm Cell Therapeutics has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%.

Company	Net Margins	Return on Equity	Return on Assets
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%

30.7% of BioXcel Therapeutics shares are owned by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 3.7% of BioXcel Therapeutics shares are owned by company insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BioXcel Therapeutics has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market.

Summary

BioXcel Therapeutics beats Brainstorm Cell Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Brainstorm Cell Therapeutics compare to Gossamer Bio?

Gossamer Bio (NASDAQ:GOSS) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

Gossamer Bio currently has a consensus target price of $5.00, suggesting a potential upside of 2,858.58%. Given Gossamer Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Gossamer Bio is more favorable than Brainstorm Cell Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Brainstorm Cell Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. 3.7% of Gossamer Bio shares are held by insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Gossamer Bio and Gossamer Bio both had 1 articles in the media. Gossamer Bio's average media sentiment score of 0.00 equaled Brainstorm Cell Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gossamer Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Brainstorm Cell Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gossamer Bio has a beta of 2, suggesting that its stock price is 100% more volatile than the broader market. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market.

Brainstorm Cell Therapeutics has lower revenue, but higher earnings than Gossamer Bio. Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	0.82	-$170.37M	-$0.79	N/A
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.64	N/A

Brainstorm Cell Therapeutics has a net margin of 0.00% compared to Gossamer Bio's net margin of -324.82%.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-324.82%	N/A	-96.10%
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%

Summary

Gossamer Bio beats Brainstorm Cell Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Brainstorm Cell Therapeutics compare to INmune Bio?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

Brainstorm Cell Therapeutics has higher earnings, but lower revenue than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.64	N/A
INmune Bio	$50K	717.66	-$45.93M	-$1.67	N/A

Brainstorm Cell Therapeutics has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market. Comparatively, INmune Bio has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market.

INmune Bio has a consensus target price of $8.00, suggesting a potential upside of 492.59%. Given INmune Bio's stronger consensus rating and higher probable upside, analysts plainly believe INmune Bio is more favorable than Brainstorm Cell Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainstorm Cell Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
INmune Bio	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.17

In the previous week, INmune Bio had 1 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 2 mentions for INmune Bio and 1 mentions for Brainstorm Cell Therapeutics. Brainstorm Cell Therapeutics' average media sentiment score of 0.00 equaled INmune Bio'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Brainstorm Cell Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
INmune Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. Comparatively, 12.7% of INmune Bio shares are owned by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are owned by insiders. Comparatively, 21.4% of INmune Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Brainstorm Cell Therapeutics' return on equity of 0.00% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%
INmune Bio	N/A	-103.03%	-77.66%

Summary

INmune Bio beats Brainstorm Cell Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Brainstorm Cell Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCLI vs. The Competition

Export

Metric	Brainstorm Cell Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$10.35M	$3.49B	$6.74B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	-0.28	20.50	25.37	23.96
Price / Sales	N/A	328.65	530.17	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	-0.69	8.26	10.76	6.41
Net Income	-$11.62M	$23.91M	$3.56B	$337.14M
7 Day Performance	8.47%	2.12%	0.99%	-1.06%
1 Month Performance	37.88%	2.40%	0.79%	0.49%
1 Year Performance	-20.53%	57.09%	30.25%	28.43%

Brainstorm Cell Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCLI Brainstorm Cell Therapeutics	0.2614 of 5 stars	$0.94 +3.0%	N/A	-23.8%	$10.35M	N/A	N/A	40
MIRA MIRA Pharmaceuticals	0.7125 of 5 stars	$0.95 +0.3%	N/A	-29.4%	$40.09M	N/A	N/A	2	News Coverage
IXHL Incannex Healthcare	1.4493 of 5 stars	$3.31 +1.8%	$18.00 +443.8%	-50.8%	$39.62M	$90K	N/A	3
BTAI BioXcel Therapeutics	1.8755 of 5 stars	$1.26 -3.1%	$11.00 +773.0%	-24.3%	$38.91M	$680K	N/A	90
GOSS Gossamer Bio	2.2939 of 5 stars	$0.17 +4.4%	$5.00 +2,817.2%	-87.8%	$38.54M	$55.54M	N/A	180

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCLI) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Brainstorm Cell Therapeutics (BCLI) Competitors

BCLI vs. MIRA, IXHL, BTAI, GOSS, and INMB

How does Brainstorm Cell Therapeutics compare to MIRA Pharmaceuticals?

Summary

How does Brainstorm Cell Therapeutics compare to Incannex Healthcare?

Summary

How does Brainstorm Cell Therapeutics compare to BioXcel Therapeutics?

Summary

How does Brainstorm Cell Therapeutics compare to Gossamer Bio?

Summary

How does Brainstorm Cell Therapeutics compare to INmune Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCLI vs. The Competition

Brainstorm Cell Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Brainstorm Cell Therapeutics (BCLI) Competitors

BCLI vs. MIRA, IXHL, BTAI, GOSS, and INMB

How does Brainstorm Cell Therapeutics compare to MIRA Pharmaceuticals?

Is BCLI or MIRA more profitable?

Which has preferable earnings & valuation, BCLI or MIRA?

Do institutionals & insiders hold more shares of BCLI or MIRA?

Which has more risk and volatility, BCLI or MIRA?

Do analysts prefer BCLI or MIRA?

Does the media refer more to BCLI or MIRA?

Summary

How does Brainstorm Cell Therapeutics compare to Incannex Healthcare?

Do institutionals and insiders have more ownership in BCLI or IXHL?

Is BCLI or IXHL more profitable?

Do analysts prefer BCLI or IXHL?

Which has better earnings & valuation, BCLI or IXHL?

Which has more risk & volatility, BCLI or IXHL?

Does the media refer more to BCLI or IXHL?

Summary

How does Brainstorm Cell Therapeutics compare to BioXcel Therapeutics?

Do analysts prefer BTAI or BCLI?

Does the media refer more to BTAI or BCLI?

Which has higher valuation & earnings, BTAI or BCLI?

Is BTAI or BCLI more profitable?

Do institutionals & insiders have more ownership in BTAI or BCLI?

Which has more volatility & risk, BTAI or BCLI?

Summary

How does Brainstorm Cell Therapeutics compare to Gossamer Bio?

Do analysts recommend GOSS or BCLI?

Do insiders & institutionals have more ownership in GOSS or BCLI?

Does the media prefer GOSS or BCLI?

Which has more risk & volatility, GOSS or BCLI?

Which has stronger valuation & earnings, GOSS or BCLI?

Is GOSS or BCLI more profitable?

Summary

How does Brainstorm Cell Therapeutics compare to INmune Bio?

Which has higher earnings & valuation, BCLI or INMB?

Which has more risk & volatility, BCLI or INMB?

Do analysts rate BCLI or INMB?

Does the media favor BCLI or INMB?

Do insiders and institutionals hold more shares of BCLI or INMB?

Is BCLI or INMB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCLI vs. The Competition

Brainstorm Cell Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools